Foster City, Calif. – February 18, 2026 – Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has announced that it will release its financial results for the fourth quarter and the full year 2025 after market close on February 25, 2026. The biopharmaceutical company, focused on developing and commercializing therapies for rare and orphan diseases, will detail its performance during a conference call the same day. This announcement comes as Mirum continues to advance its pipeline, including its lead product, LIVMARLI (maralixibat), and expand its commercial footprint.
Investors and stakeholders are keenly watching Mirum Pharmaceuticals as the company navigates the competitive landscape of rare disease treatments. The company’s stock has seen significant growth, with a 33.05% year-to-date increase as of February 18, 2026, according to Yahoo Finance data. Source The upcoming earnings report will provide crucial insights into the company’s revenue growth, expenses, and overall financial health, particularly in light of its commercialization efforts for LIVMARLI and Cholbam.
Financial Performance and Key Metrics
Mirum Pharmaceuticals’ third fiscal quarter of 2025, which ended September 30, 2025, showed revenue of $133.01 million, a 47.17% year-over-year increase. Source Operating expenses for the same period totaled $104.87 million, representing a 27.49% increase. Net income for the quarter reached $2.90 million, a substantial 120.41% increase, resulting in a net profit margin of 2.18%. Earnings per share were reported at $0.05, a 116.67% increase. EBITDA for the quarter was $8.66 million, a 230% increase.
The company’s market capitalization currently stands at $6.293 billion, with approximately 51.68 million shares outstanding. Source Analysts have set a 1-year target estimate of $114.70 for the stock, reflecting continued optimism about Mirum’s potential. The company’s beta, a measure of volatility, is 0.50.
Pipeline and Commercialization Efforts
Mirum’s primary focus remains on LIVMARLI, an orally administered IBAT inhibitor approved for treating cholestatic pruritus in patients with Alagille syndrome. The company is also actively commercializing Cholbam, a treatment for bile acid synthesis disorders, and Chenodal, used for treating gallbladder stones and currently in Phase 3 development for cerebrotendinous xanthomatosis. These therapies address significant unmet needs in the rare disease community.
Recent analyst activity indicates growing confidence in Mirum’s prospects. RBC Capital initiated coverage with an Outperform rating on February 17, 2026, while TD Cowen raised the price target to $115 from $95 on January 29, 2026. Source a director of Mirum Pharmaceuticals recently purchased $9.0 million in common stock, signaling strong internal confidence in the company’s future. Source
Conference Call Details
Mirum Pharmaceuticals will host a conference call to discuss the financial results and provide a business update on February 25, 2026, at 4:30 PM Eastern Time. Details regarding access to the call will be available on the company’s investor relations website. Investors and analysts are encouraged to participate to gain further insights into Mirum’s performance and strategic direction.
Looking ahead, the company’s ability to successfully execute its commercial strategy for LIVMARLI and advance its pipeline will be critical to its continued growth. The fourth quarter and year-finish 2025 results will provide a valuable benchmark for assessing Mirum’s progress and its position within the rare disease pharmaceutical sector.
Stay informed on Mirum Pharmaceuticals’ developments and share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and does not constitute medical or financial advice. Consult with a qualified healthcare professional or financial advisor for personalized guidance.
